SEATTLE, March 2, 2016 /PRNewswire/ -- Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients, today announced that data from the VENUS trial showing the discordance between clinical impressions of patients with systemic inflammation will be presented at the upcoming 36th International Symposium on Intensive Care and Emergency Medicine on Mar. 15 in Brussels, Belgium.
Poster Title: "Analysis of Discordance Between the Clinical Impressions of Patients with Systemic Inflammation: Results of a Prospective Non-Interventional Trial (VENUS)"
Presenter: Dr. Bert Lopansri
Date: March 15, 2016
Time: 6 p.m. CET
Location: Exhibition Hall
Additional information may be found at http://www.intensive.org
Sepsis is a life-threatening condition that arises when the body's response to infection damages its own tissues and organs. Confirming a sepsis diagnosis today aims to identify the pathogen only and therefore has serious limitations in respect of speed and sensitivity. The Immunexpress SeptiCyte™ LAB solution evaluates the host immune response to aid clinicians in quickly and accurately diagnosing sepsis in patients suspected of sepsis.
Immunexpress is a Seattle-based molecular diagnostic company committed to improving outcomes for patients suspected of sepsis. Immunexpress's SeptiCyte™ technology quantifies directly from whole blood specific molecular markers from the patient's own immune system – the "host response." Detecting the host's septic immune response has the potential to identify sepsis earlier and more accurately than current sepsis diagnostics that focus on identifying the invading pathogen because it is independent of whether or not the pathogen is in the blood sample. Immunexpress's pipeline includes monitoring assays for readily available platforms, including point-of-care (POC) sample-to-answer instrumentation. For more information visit www.Immunexpress.com.
SOURCE Immunexpress, Inc.